Market Analysis on Organ Transplant Immunosuppressant Drugs Industry – Insights for Corporate Strategy and R&D
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Organ Transplant Immunosuppressant Drugs Market from 2024 to 2025?
In recent times, there has been a consistent growth in the organ transplant immunosuppressant drugs market. It is projected that the market, which was valued at $5.35 billion in 2024 will expand to reach $5.52 billion in 2025, marking a compound annual growth rate (CAGR) of 3.2%. The rise during the historic period is credited to factors such as the growth in transplant procedures, enhancement in healthcare infrastructure, progress in research and development, the global increase in the aging population, and heightened awareness.
What Is the Projected Market Size of the Organ Transplant Immunosuppressant Drugs Market?
The market size for immunosuppressant drugs used in organ transplants is projected to experience continuous growth in the coming years. It is anticipated to expand to “$6.61 billion by 2029, growing at a compound annual growth rate (CAGR) of 4.6%. Factors contributing to this growth during the forecast period include the emergence of new therapies, increase in the occurrence of organ failures, advancements in personalized medicine, worldwide health initiatives, and collaborative international efforts. Significant trends expected during this period involve technological innovations, advancements, strategies for cost containment, market amalgamation and partnerships, and a rise in the number of organ transplants.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10143&type=smp
Who are the Major Competitors in the Organ Transplant Immunosuppressant Drugs Market Outlook?
Major companies operating in the organ transplant immunosuppressant drugs market include Astellas Pharma Inc., F. Hoffmann-La Roche AG, Novartis AG, Accord Healthcare Limited, GlaxoSmithKline PLC, Pfizer Inc., Sanofi S.A., Alsachim a Shimadzu Group Company, Neovii Pharmaceuticals AG, Zydus Lifesciences Limited, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Mylan N.V., Strides Pharma Global Pte Ltd., Asahi Kasei Corporation, Bristol-Myers Squibb Company, Veloxis Pharmaceuticals A/S, Viatris Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Hansa Biopharma AB, Wockhardt Ltd, Glenmark Pharmaceuticals Ltd., Biocon Ltd., Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Intas Pharmaceuticals Limited, Alkem Laboratories Limited, Torrent Pharmaceuticals Limited
What Is Fueling Growth in the Organ Transplant Immunosuppressant Drugs Market?
The growth of the organ transplant immunosuppressant drugs market is being propelled by a rising demand for organ transplants. This surgical procedure involves substituting a sick or defective organ in a human body with a healthy one from a donor. This life-saving technique enables the replacement of impaired or failed organs with healthy ones from a donor. The need for immunosuppressant drugs is critical in order to avoid the rejection of the transplanted organs, which could lead to organ rejection. The accessibility and efficacy of these drugs determine the success of an organ transplant. For example, the Organ Procurement and Transplantation Network (OPTN), a public-private company based in the U.S., reported that about 16,335 individuals donated one or more organs after their death in 2023. This is the first time the number of deceased donors has exceeded 15,000, signifying a 9.6% rise from 2022. Therefore, the augmenting demand for organ transplantations is set to catalyze the organ transplant immunosuppressant drugs market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10143&type=smp
Which Organ Transplant Immunosuppressant Drugs Market Segments Are Growing the Fastest?
The organ transplant immunosuppressant drugs market covered in this report is segmented –
1) By Drug Class: Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids, Others Drug Classes
2) By Transplant Type: Heart, Kidney, Liver, Lung, Pancreas, Other Transplant Types
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Calcineurin Inhibitors: Cyclosporine, Tacrolimus
2) By Antiproliferative Agents: Azathioprine, Mycophenolate Mofetil, Mycophenolic Acid
3) By MTOR Inhibitor: Sirolimus, Everolimus
4) By Steroids: Prednisone, Methylprednisolone
5) By Other Drug Classes: Costimulation Blockers, Sodium Channel Blockers, Antibody-Based Therapies
Which Industry Trends Are Shaping the Future of the Organ Transplant Immunosuppressant Drugs Market?
In the market for organ transplant immunosuppressant drugs, there is a notable trend towards product innovation. In order to remain competitive, key players in this market are prioritizing the creation of novel solutions like combination therapy. The adoption of combination therapy, which uses more than one immunosuppressant drug, is on the rise because it can enhance immunosuppression and lower the chances of adverse effects. An example is the approval by the U.S. Food and Drug Administration (FDA) of OPSYNVI, a product of the US pharmaceutical and biotech firm Johnson & Johnson in March 2024. OPSYNVI, a single pill combining tadalafil (a phosphodiesterase 5 inhibitor) and macitentan (an endothelin receptor antagonist), is set to be used for long-duration management of pulmonary arterial hypertension (PAH). It can be administered to PAH patients who have not been treated before or are currently under treatment with an ERA, a PDE5 inhibitor, or both. OPSYNVI can also be recommended to patients regularly taking separate doses of 10mg macitentan and 40mg tadalafil (20mg x 2).
Access The Full Report Here:
Which Countries Are Leading the Organ Transplant Immunosuppressant Drugs Market?
North America was the largest region in the organ transplant immunosuppressant drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global organ transplant immunosuppressant drugs market report during the forecast period. The regions covered in the organ transplant immunosuppressant drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10143
This Report Delivers Insight On:
1. How big is the organ transplant immunosuppressant drugs market, and how is it changing globally?
2. Who are the major companies in the organ transplant immunosuppressant drugs market, and how are they performing?
3. What are the key opportunities and risks in the organ transplant immunosuppressant drugs market right now?
4. Which products or customer segments are growing the most in the organ transplant immunosuppressant drugs market?
5. What factors are helping or slowing down the growth of the organ transplant immunosuppressant drugs market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
